MoHAP and SFDA Discuss Means of Enhancing Cooperation in the Pharmaceutical Industry

Published Saturday, 19 October 2019

The Assistant Undersecretary of the Ministry of Health and Prevention’s Public Health Policy and Licenses, HE Dr. Amin Hussein Al Amiri recently received at MoHAP headquarters HE Dr. Hisham bin Saad Al-Jadhey, CEO of the Saudi Food and Drug Authority (SFDA).The meeting reviewed the cooperation relations between the two countries in the healthcare services field, especially in the pharmaceutical industry and the mechanisms of developing policies and legislations to keep abreast with the latest international updates.

Dr. Ruqaya Aqeel Al Bastaki, Director of the Department of Medicine, Mr. Abdel Nasser Bensalem, Expert in Health Legislation, Dr. Rasha El Sayed Salama, Public Health Counselor, and Dr. Rita Shalouhi, Expert in Pharmaceutical Policies were present at the meeting.

Meanwhile, Dr Sami AlSager, Vice President for Operations, Dr. Saleh Aldosari. Vice President for Food Sector, Ms. Ghandourah Shams Ghandourah, Director of International Cooperation Department, Faisal Abdul Aziz Askar, Chief of Protocol also attended the meeting, representing the Saudi Food and Drug Authority (SFDA).

Means of Developing Mutual Cooperation and Sharing Experiences

During the meeting, the two sides explored means of developing cooperation and sharing experiences, expanding the scope of coordination in various fields.

Joint Capability Areas

Welcoming the CEO of the Saudi Food and Drug Authority, Dr. Al Amiri highlighted the positive role of both MoHAP and SFDA in reinforcing the long-established brotherly relationship, pointing to the available opportunities to take advantage of potential and expertise of both sides in delivering the best medical services.

Al Amiri shed light on MoHAP’s achievements in developing the pharmaceutical industry, establishing a competitive environment to attract international pharmaceutical companies, encouraging medical research in the pharmaceutical industry field.

“This has contributed to making the UAE one of the most attractive countries to innovative and vital pharmaceutical industries, thanks to its great infrastructure and human resources. It is therefore not surprising the sustained qualitative and quantitative growth we’re witnessing in the healthcare sector,” he added.

Fostering Opportunities for Cooperation and Investment Between SFDA and MoHAP

Commending the warm welcome, HE Dr. Hisham bin Saad Al-Jadhey expressed his happiness with the development of the bilateral relations, lauding the extraordinary level of the UAE’s health system, the flexible legislative environment, the medical infrastructure, and the organization of international medical exhibitions and conferences.

Al-Jadhey emphasized the SFDA’s keenness on enhancing opportunities for cooperation and investment with MoHAP, especially in the pharmaceutical products field.

Did you find the content useful ?

Give us your feedback so we can improve your experience


Help us improve MOHAP website

Give us your feedback so we can improve your experience

Thank you for your feedback.